AB0478 Glucocorticoid Prevents The Progression of Atherosclerosis in Japanese Patients with Systemic Lupus Erythematosus: A Longitudinal Prospective Cohort Study (NTMC-Cohort Study)

BackgroundSeveral cross-sectional studies have shown a progression of atherosclerosis in systemic lupus erythematosus (SLE) was associated with the activity of SLE but not with glucocorticoid therapy. However, a few evidence showed the correlations between the progression of atherosclerosis in SLE a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.1069-1070
Hauptverfasser: Iwasaki, M., Ushikubo, M., Izumi, K., Akiya, K., Oshima, H.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1070
container_issue Suppl 2
container_start_page 1069
container_title Annals of the rheumatic diseases
container_volume 75
creator Iwasaki, M.
Ushikubo, M.
Izumi, K.
Akiya, K.
Oshima, H.
description BackgroundSeveral cross-sectional studies have shown a progression of atherosclerosis in systemic lupus erythematosus (SLE) was associated with the activity of SLE but not with glucocorticoid therapy. However, a few evidence showed the correlations between the progression of atherosclerosis in SLE and glucocorticoid therapy in longitudinal studies. Moreover, races and regions are known to be important in atherosclerosis.ObjectivesWe conducted a longitudinal prospective cohort study to clarify relevant clinical factors to influence the progression of atherosclerosis in Japanese patients with SLE.MethodsIn our cohort of the patients with SLE who regularly visit our department, the patients who underwent echography of the carotid arteries twice or more, with an interval of two years or more, were enrolled into the present study.Atherosclerosis was evaluated with echography of the carotid arteries. A mean of the bilateral intimal carotid artery media thickness (mIMT) was measured with the three-point method (TOSHIBA Xario200, Aplio400). The annual progression rate of mIMT (mIMT/y) was calculated from the difference between the baseline and the subsequent echo studies.We analyzed clinical factors associated with mIMT and mIMT/y using multiple regression analysis. For mIMT, clinical factors assessed in the analysis were as follows: age, disease duration, smoking habits, comorbid conditions, total cumulative prednisolone dosage (tPSL), history of other medications, SLICC/ACR damage index (SDI), Ankle-Brachial Index, Cardio-Ankle Vascular Index, HbA1c, C-reactive protein, serum creatinine, high density lipoprotein cholesterol, and low density lipoprotein cholesterol at baseline. For mIMT/y, in addition to the factors above, we assessed mean daily prednisolone dosage during the follow-up period (mPSL) and other medications during the follow-up period.The analysis was performed by SPSS version 20.Data were represented as median (25–75 percentile).ResultsThirty-nine Japanese patients with SLE were recruited in our study. Of these, 35 were women; age, disease duration, tPSL at baseline, and daily prednisolone dosage during the follow-up period (mPSL) were 60 (48–65) years, 25 (12–32) years, 58 (36–82) g and 5.0 (4.0–7.5) mg/day, respectively. The intervals of echo studies were 4.0 (2.7–6.1) years.At baseline, the mIMT was 0.60 (0.50–0.75) mm. Age (B=0.005, SE=0.002, p=0.011) and SDI (B=0.05, SE=0.02, p=0.019) were selected as positive contributory factors for mIMT, wh
doi_str_mv 10.1136/annrheumdis-2016-eular.2333
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1902055325</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322516505</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1275-389dd37d8c36d16452dc81e66ab4cff573984f9aa90b9f5bfaee69c653819f053</originalsourceid><addsrcrecordid>eNqVkc1u1DAURi0EEkPhHSx1A4sUO04cG1bDqJSiKSB1WFuOYzceJXHwT6vZseGZ-j48SZ0Oi27Z2LrX37GvdQA4xegMY0Lfy2nyvU5jZ0NRIkwLnQbpz0pCyDOwwhVluU3Rc7BCCJGi4rR5CV6FsM8lYpitwP36E6oa9vf3n4shKaecj1Y528EfXt_qKQa463Uu3I3XIVg3QWfgOvbau6CGZbUB2gl-lbOcdMhRGe0jd2djD68PIerRKrhNcwrw3B8yOsroQgof4Bpu3XRjY-rsJIfllTBrFe2thhvX51HgdT47wLffdleb4mnr3Wvwwsgh6Df_9hPw8_P5bvOl2H6_uNyst0WLy6YuCONdR5qOKUI7TKu67BTDmlLZVsqYuiGcVYZLyVHLTd0aqTXlitaEYW5QTU7A6fHe2btfSYco9i75PG0QmKMS1TUpl9THY0rlLwSvjZi9HaU_CIzEYko8MSUWU-LRlFhMZZoe6Xbc_xf4AMpZpBo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1902055325</pqid></control><display><type>article</type><title>AB0478 Glucocorticoid Prevents The Progression of Atherosclerosis in Japanese Patients with Systemic Lupus Erythematosus: A Longitudinal Prospective Cohort Study (NTMC-Cohort Study)</title><source>BMJ Journals - NESLi2</source><creator>Iwasaki, M. ; Ushikubo, M. ; Izumi, K. ; Akiya, K. ; Oshima, H.</creator><creatorcontrib>Iwasaki, M. ; Ushikubo, M. ; Izumi, K. ; Akiya, K. ; Oshima, H.</creatorcontrib><description>BackgroundSeveral cross-sectional studies have shown a progression of atherosclerosis in systemic lupus erythematosus (SLE) was associated with the activity of SLE but not with glucocorticoid therapy. However, a few evidence showed the correlations between the progression of atherosclerosis in SLE and glucocorticoid therapy in longitudinal studies. Moreover, races and regions are known to be important in atherosclerosis.ObjectivesWe conducted a longitudinal prospective cohort study to clarify relevant clinical factors to influence the progression of atherosclerosis in Japanese patients with SLE.MethodsIn our cohort of the patients with SLE who regularly visit our department, the patients who underwent echography of the carotid arteries twice or more, with an interval of two years or more, were enrolled into the present study.Atherosclerosis was evaluated with echography of the carotid arteries. A mean of the bilateral intimal carotid artery media thickness (mIMT) was measured with the three-point method (TOSHIBA Xario200, Aplio400). The annual progression rate of mIMT (mIMT/y) was calculated from the difference between the baseline and the subsequent echo studies.We analyzed clinical factors associated with mIMT and mIMT/y using multiple regression analysis. For mIMT, clinical factors assessed in the analysis were as follows: age, disease duration, smoking habits, comorbid conditions, total cumulative prednisolone dosage (tPSL), history of other medications, SLICC/ACR damage index (SDI), Ankle-Brachial Index, Cardio-Ankle Vascular Index, HbA1c, C-reactive protein, serum creatinine, high density lipoprotein cholesterol, and low density lipoprotein cholesterol at baseline. For mIMT/y, in addition to the factors above, we assessed mean daily prednisolone dosage during the follow-up period (mPSL) and other medications during the follow-up period.The analysis was performed by SPSS version 20.Data were represented as median (25–75 percentile).ResultsThirty-nine Japanese patients with SLE were recruited in our study. Of these, 35 were women; age, disease duration, tPSL at baseline, and daily prednisolone dosage during the follow-up period (mPSL) were 60 (48–65) years, 25 (12–32) years, 58 (36–82) g and 5.0 (4.0–7.5) mg/day, respectively. The intervals of echo studies were 4.0 (2.7–6.1) years.At baseline, the mIMT was 0.60 (0.50–0.75) mm. Age (B=0.005, SE=0.002, p=0.011) and SDI (B=0.05, SE=0.02, p=0.019) were selected as positive contributory factors for mIMT, while tPSL was selected as a negative factor (B=-0.002, SE=0.001, p=0.007).For mIMT/y, mPSL (B=-0.005, SE=0.002, p=0.004) was a negative contributory factor, and diabetes mellitus requiring medical therapy was a positive factor (B=0.032, SE=0.014, p=0.035).ConclusionsThese results suggested that glucocorticoid therapy might be protective against the progression of atherosclerosis in Japanese patients with SLE.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2016-eular.2333</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><ispartof>Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1069-1070</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/75/Suppl_2/1069.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/75/Suppl_2/1069.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,315,781,785,3197,23575,27928,27929,77604,77635</link.rule.ids></links><search><creatorcontrib>Iwasaki, M.</creatorcontrib><creatorcontrib>Ushikubo, M.</creatorcontrib><creatorcontrib>Izumi, K.</creatorcontrib><creatorcontrib>Akiya, K.</creatorcontrib><creatorcontrib>Oshima, H.</creatorcontrib><title>AB0478 Glucocorticoid Prevents The Progression of Atherosclerosis in Japanese Patients with Systemic Lupus Erythematosus: A Longitudinal Prospective Cohort Study (NTMC-Cohort Study)</title><title>Annals of the rheumatic diseases</title><description>BackgroundSeveral cross-sectional studies have shown a progression of atherosclerosis in systemic lupus erythematosus (SLE) was associated with the activity of SLE but not with glucocorticoid therapy. However, a few evidence showed the correlations between the progression of atherosclerosis in SLE and glucocorticoid therapy in longitudinal studies. Moreover, races and regions are known to be important in atherosclerosis.ObjectivesWe conducted a longitudinal prospective cohort study to clarify relevant clinical factors to influence the progression of atherosclerosis in Japanese patients with SLE.MethodsIn our cohort of the patients with SLE who regularly visit our department, the patients who underwent echography of the carotid arteries twice or more, with an interval of two years or more, were enrolled into the present study.Atherosclerosis was evaluated with echography of the carotid arteries. A mean of the bilateral intimal carotid artery media thickness (mIMT) was measured with the three-point method (TOSHIBA Xario200, Aplio400). The annual progression rate of mIMT (mIMT/y) was calculated from the difference between the baseline and the subsequent echo studies.We analyzed clinical factors associated with mIMT and mIMT/y using multiple regression analysis. For mIMT, clinical factors assessed in the analysis were as follows: age, disease duration, smoking habits, comorbid conditions, total cumulative prednisolone dosage (tPSL), history of other medications, SLICC/ACR damage index (SDI), Ankle-Brachial Index, Cardio-Ankle Vascular Index, HbA1c, C-reactive protein, serum creatinine, high density lipoprotein cholesterol, and low density lipoprotein cholesterol at baseline. For mIMT/y, in addition to the factors above, we assessed mean daily prednisolone dosage during the follow-up period (mPSL) and other medications during the follow-up period.The analysis was performed by SPSS version 20.Data were represented as median (25–75 percentile).ResultsThirty-nine Japanese patients with SLE were recruited in our study. Of these, 35 were women; age, disease duration, tPSL at baseline, and daily prednisolone dosage during the follow-up period (mPSL) were 60 (48–65) years, 25 (12–32) years, 58 (36–82) g and 5.0 (4.0–7.5) mg/day, respectively. The intervals of echo studies were 4.0 (2.7–6.1) years.At baseline, the mIMT was 0.60 (0.50–0.75) mm. Age (B=0.005, SE=0.002, p=0.011) and SDI (B=0.05, SE=0.02, p=0.019) were selected as positive contributory factors for mIMT, while tPSL was selected as a negative factor (B=-0.002, SE=0.001, p=0.007).For mIMT/y, mPSL (B=-0.005, SE=0.002, p=0.004) was a negative contributory factor, and diabetes mellitus requiring medical therapy was a positive factor (B=0.032, SE=0.014, p=0.035).ConclusionsThese results suggested that glucocorticoid therapy might be protective against the progression of atherosclerosis in Japanese patients with SLE.Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkc1u1DAURi0EEkPhHSx1A4sUO04cG1bDqJSiKSB1WFuOYzceJXHwT6vZseGZ-j48SZ0Oi27Z2LrX37GvdQA4xegMY0Lfy2nyvU5jZ0NRIkwLnQbpz0pCyDOwwhVluU3Rc7BCCJGi4rR5CV6FsM8lYpitwP36E6oa9vf3n4shKaecj1Y528EfXt_qKQa463Uu3I3XIVg3QWfgOvbau6CGZbUB2gl-lbOcdMhRGe0jd2djD68PIerRKrhNcwrw3B8yOsroQgof4Bpu3XRjY-rsJIfllTBrFe2thhvX51HgdT47wLffdleb4mnr3Wvwwsgh6Df_9hPw8_P5bvOl2H6_uNyst0WLy6YuCONdR5qOKUI7TKu67BTDmlLZVsqYuiGcVYZLyVHLTd0aqTXlitaEYW5QTU7A6fHe2btfSYco9i75PG0QmKMS1TUpl9THY0rlLwSvjZi9HaU_CIzEYko8MSUWU-LRlFhMZZoe6Xbc_xf4AMpZpBo</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Iwasaki, M.</creator><creator>Ushikubo, M.</creator><creator>Izumi, K.</creator><creator>Akiya, K.</creator><creator>Oshima, H.</creator><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201606</creationdate><title>AB0478 Glucocorticoid Prevents The Progression of Atherosclerosis in Japanese Patients with Systemic Lupus Erythematosus: A Longitudinal Prospective Cohort Study (NTMC-Cohort Study)</title><author>Iwasaki, M. ; Ushikubo, M. ; Izumi, K. ; Akiya, K. ; Oshima, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1275-389dd37d8c36d16452dc81e66ab4cff573984f9aa90b9f5bfaee69c653819f053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iwasaki, M.</creatorcontrib><creatorcontrib>Ushikubo, M.</creatorcontrib><creatorcontrib>Izumi, K.</creatorcontrib><creatorcontrib>Akiya, K.</creatorcontrib><creatorcontrib>Oshima, H.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iwasaki, M.</au><au>Ushikubo, M.</au><au>Izumi, K.</au><au>Akiya, K.</au><au>Oshima, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0478 Glucocorticoid Prevents The Progression of Atherosclerosis in Japanese Patients with Systemic Lupus Erythematosus: A Longitudinal Prospective Cohort Study (NTMC-Cohort Study)</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2016-06</date><risdate>2016</risdate><volume>75</volume><issue>Suppl 2</issue><spage>1069</spage><epage>1070</epage><pages>1069-1070</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundSeveral cross-sectional studies have shown a progression of atherosclerosis in systemic lupus erythematosus (SLE) was associated with the activity of SLE but not with glucocorticoid therapy. However, a few evidence showed the correlations between the progression of atherosclerosis in SLE and glucocorticoid therapy in longitudinal studies. Moreover, races and regions are known to be important in atherosclerosis.ObjectivesWe conducted a longitudinal prospective cohort study to clarify relevant clinical factors to influence the progression of atherosclerosis in Japanese patients with SLE.MethodsIn our cohort of the patients with SLE who regularly visit our department, the patients who underwent echography of the carotid arteries twice or more, with an interval of two years or more, were enrolled into the present study.Atherosclerosis was evaluated with echography of the carotid arteries. A mean of the bilateral intimal carotid artery media thickness (mIMT) was measured with the three-point method (TOSHIBA Xario200, Aplio400). The annual progression rate of mIMT (mIMT/y) was calculated from the difference between the baseline and the subsequent echo studies.We analyzed clinical factors associated with mIMT and mIMT/y using multiple regression analysis. For mIMT, clinical factors assessed in the analysis were as follows: age, disease duration, smoking habits, comorbid conditions, total cumulative prednisolone dosage (tPSL), history of other medications, SLICC/ACR damage index (SDI), Ankle-Brachial Index, Cardio-Ankle Vascular Index, HbA1c, C-reactive protein, serum creatinine, high density lipoprotein cholesterol, and low density lipoprotein cholesterol at baseline. For mIMT/y, in addition to the factors above, we assessed mean daily prednisolone dosage during the follow-up period (mPSL) and other medications during the follow-up period.The analysis was performed by SPSS version 20.Data were represented as median (25–75 percentile).ResultsThirty-nine Japanese patients with SLE were recruited in our study. Of these, 35 were women; age, disease duration, tPSL at baseline, and daily prednisolone dosage during the follow-up period (mPSL) were 60 (48–65) years, 25 (12–32) years, 58 (36–82) g and 5.0 (4.0–7.5) mg/day, respectively. The intervals of echo studies were 4.0 (2.7–6.1) years.At baseline, the mIMT was 0.60 (0.50–0.75) mm. Age (B=0.005, SE=0.002, p=0.011) and SDI (B=0.05, SE=0.02, p=0.019) were selected as positive contributory factors for mIMT, while tPSL was selected as a negative factor (B=-0.002, SE=0.001, p=0.007).For mIMT/y, mPSL (B=-0.005, SE=0.002, p=0.004) was a negative contributory factor, and diabetes mellitus requiring medical therapy was a positive factor (B=0.032, SE=0.014, p=0.035).ConclusionsThese results suggested that glucocorticoid therapy might be protective against the progression of atherosclerosis in Japanese patients with SLE.Disclosure of InterestNone declared</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/annrheumdis-2016-eular.2333</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1069-1070
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1902055325
source BMJ Journals - NESLi2
title AB0478 Glucocorticoid Prevents The Progression of Atherosclerosis in Japanese Patients with Systemic Lupus Erythematosus: A Longitudinal Prospective Cohort Study (NTMC-Cohort Study)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T00%3A48%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0478%E2%80%85Glucocorticoid%20Prevents%20The%20Progression%20of%20Atherosclerosis%20in%20Japanese%20Patients%20with%20Systemic%20Lupus%20Erythematosus:%20A%20Longitudinal%20Prospective%20Cohort%20Study%20(NTMC-Cohort%20Study)&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Iwasaki,%20M.&rft.date=2016-06&rft.volume=75&rft.issue=Suppl%202&rft.spage=1069&rft.epage=1070&rft.pages=1069-1070&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2016-eular.2333&rft_dat=%3Cproquest_cross%3E4322516505%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1902055325&rft_id=info:pmid/&rfr_iscdi=true